Guest guest Posted October 6, 2003 Report Share Posted October 6, 2003 I agree if you mean that systematic scientific investigation should allow for the special one-to-one nature of CM treatment. Western scientists are slowly coming to accept that (Bigler et al, 2003). Yip et al (2003) conclude that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. THUS, NEW STANDARDS NEED TO BE DEVELOPED FOR THE EVALUATION OF HERBAL MEDICINE. >>>Even within there own paradigms things are changing. For example my Dad as published studies on schizophrenia using methodologies that are not reductionist and never the less they were published. This was a big step but things are changing Alon Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 6, 2003 Report Share Posted October 6, 2003 Can you give me a link for this PC-SPECS study? I don't see why this product should be analyzed by new standards, since its active ingredients were already proven to be hidden drugs (zanax, wayfarin, DES). At least two years ago, this was hardly an 'herbal product'. Is there a new, 'clean' version out there? On Monday, October 6, 2003, at 08:16 PM, Alon Marcus wrote: > I agree if you mean that systematic scientific investigation should > allow for the special one-to-one nature of CM treatment. Western > scientists are slowly coming to accept that (Bigler et al, 2003). Yip > et al (2003) conclude that PC-SPES cannot be evaluated by the > same standards established to test synthetic pharmaceutical > compounds. THUS, NEW STANDARDS NEED TO BE > DEVELOPED FOR THE EVALUATION OF HERBAL MEDICINE. >>>> Even within there own paradigms things are changing. For example my >>>> Dad as published studies on schizophrenia using methodologies that >>>> are not reductionist and never the less they were published. This >>>> was a big step but things are changing > Alon > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 7, 2003 Report Share Posted October 7, 2003 Hi All, & Hi Wainright, [susan, if the VBMA server bounces this because of size, could YOU please mount it for me. IMO, Westerm Medicine has reached an impasse in the Tx of prostate cancer [PC] and serious work, at last, is being directed to herbal medicine in PC Tx.] Wainright wrote: > ... if we wish Chinese medicine as we know it to survive ... IMO, Chinese medicine WILL survive, but NOT as we know it now! CM will evolve to embrace established [and yet to be established] medical and social facts from the West. Parallel with the evolution of CM, we will probably see evolution in Western medicine (WM) to embrace established [and yet to be established] medical and social facts from the East. In the evolutions of CM and WM, we will see more and more cross- linkages - integration - so that in time the two systems will grow closer and closer together. It remains to be seen whether this will take 5, 50, 500, or 5000 years, but sooner or later we will have an integrated medicine of the best available. > ... an important task is for us to exert political pressure to NOT > subject CM to any type of systematic scientific investigation ... With respect, I disagree. IMO, systematic scientific investigation offers the BEST hope for the development of effective, objective medicine. It will identify and eliminate (or correct) the fallacies and will highlight and improve the effective methods. > ... or at the very least, to preserve a high measure of autonomy > for CM in the process. Wainwright Wainright, in developing my argument, I will use recent references from Medline on prostate cancer. Thomson et al (2002) wrote: " Because of the woeful ineffectiveness of standard treatment modalities on the overall survival rate from PC in the past 50 years, a more radical approach to the treatment of this cancer is justified " . By " radical approach " , they meant consideration of herbal medicine - in this case PC-SPES!! I agree if you mean that systematic scientific investigation should allow for the special one-to-one nature of CM treatment. Western scientists are slowly coming to accept that (Bigler et al, 2003). Yip et al (2003) conclude that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. THUS, NEW STANDARDS NEED TO BE DEVELOPED FOR THE EVALUATION OF HERBAL MEDICINE. Critical scientific research is starting to identify the most important active ingredients in effective CHM formulae, for example baicalin and oridonin in PC-SPES. See Hsieh et al (2002) and Marks et al (2003). PC-SPES got a bad name when it was found to have been contaminated by DES, indomethacin, warfarin etc. Before then, many cancer specialists ACCEPTED that it was of great clinical value. After the scandal broke, some specialists believed that its clinical effects were due to the CONTAMINANTS, especially DES (Wadsworth et al, 2003). However, other papers suggest that this is not the case; the clinical effects of PC-SPES do not depend on DES (Bonham et al, 2002). Western research will show that herbal formulas are not all goodness and light, with no side effects. For example, though the clinical efficacy of PC-SPES in prostate cancer is well accepted now [in spite of the FDA ban!], its oestrogenic effects have their negative consequences in men. It is beginning to look that PC- SPES is a form of phytochemical castration, just as chemical androgen ablation is (Marks et al, 2003; Raffi et al, 2002; Schiff et al, 2002). Also, scientists are beginning to realise that the activity of a single herb cannot account for the overall effects of the effective formula (Hsieh & Wu, 2002). One of the great benefits of systematic western research on herbs is that a formula initially used for one condition (for example PC- SPES in prostate cancer) may be found to have OTHER clinical uses. For example Huerta et al (2002).al found that PC-SPES is also effective in colon cancer. Ikezoe et al (2003) found that PC- SPES also is effective in leukaemia. Sliva et al (2003) found that Ganoderma (Lingzhi) in PC-SPES inhibits mammary cancer as well as PC. These are GREAT breakthroughs for herbal medicine in the west! Here follows a sobering abstract about the current status of WESTERN approaches to PC: Small EJ, Harris KA. Secondary hormonal manipulation of prostate cancer. Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):24-30. Urologic Oncology Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA. Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced PC is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease progression. Patients with hormone-resistant PC (HRPC) have a median survival of approximately 18 months, and no therapy has yet shown a definitive survival advantage. However, in the past several years, a number of promising new treatment strategies have emerged. One of the most important new treatment strategies involves SECONDARY HORMONAL MANIPULATION after the failure of primary androgen deprivation. This approach is predicated on the recognition that HRPC is a heterogeneous disease, and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone. Copyright 2002, Elsevier Science (USA). All rights reserved. Publication Types: Review Review Literature PMID: 12198635 [PubMed - indexed for MEDLINE] [Phil's comment: Watch this space! For “SECONDARY HORMONAL MANIPULATION” (above), read: “HORMONAL MANIPULATION BY CHINESE MEDICINE!” Because of western bigotry, skepticism, prejudice or arrogance, IMO, Chinese Science alone will NOT be sufficient to put CM " on the map " in the Western World [i.e. to make it acceptable to western scientists]. Only WESTERN science, or at least critical Western confirmation of Chinese findings, will do that. Best regards, Phil PS: See the other cited references, below. Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene. 2003 Feb 27;22(8):1261-72. Department of Molecular Physiology and Biological Physics and Cancer Center, University of Virginia, Health Sciences Center, Charlottesville, VA 22908, USA. The use of botanical mixtures is commonplace in patients with PC, yet most of these products have not been tested rigorously in clinical trials. PC-SPES has been shown to be effective in clinical trials in patients with PC. Here we use PC-SPES as a model system to show 'proof of principle' as to how gene expression profiling coupled with promoter assays can evaluate the effect of herbal cocktails on human PC. We also show how such approaches may be used to standardize herbal extract activity by comparing the gene profile of PC-SPES with that of PC- CARE, a product with a similar herbal composition. Since prior studies have shown that PC-SPES contains estrogenic organic compounds, and such compounds are known to affect PC, an important issue is whether these are the primary drivers of the gene profile. Our data suggest that gene expression profiles of LNCaP human PC cells in response to PC-SPES are different from those found when DES, a synthetic estrogen, is used. This suggests that the estrogenic moieties within PC-SPES do not drive this expression signature. In contrast, the expression profile of PC- CARE was almost identical to that of DES, highlighting that mixtures containing similar herbal compositions do not necessarily result in similar biological activities. Interestingly, these three agents cause similar in vitro morphological changes and growth effects on LNCaP. To validate the expression profiling data, we evaluated the protein expression and promoter activity of PSA, a gene induced by PC-SPES but repressed by DES. In order to gain a mechanistic understanding of how PC-SPES and DES affect PSA expression differently, LNCaP cells were transiently transfected with wild-type and mutagenized PSA promoter, ARE concatemers and appropriate controls. We provide evidence that androgen response elements (ARE) II and III within the promoter region are responsible for the suppressive effects of DES and stimulatory effects of PC-SPES. In addition, we show that the effects on PSA transcription are ARE specific in the case of DES while PC-SPES affects this promoter nonspecifically. Expression profiling coupled with mechanistic target validation yield valuable clues as to the mode of action of complex botanical mixtures and provides a new way to compare objectively mixtures with similar components either for effect or quality assurance prior to their use in clinical trials. PMID: 12606954 [PubMed - indexed for MEDLINE] Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res. 2002 Jul 15;62(14):3920-4. Divisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. Clinical trials of the herbal preparation PC-SPES showed substantial responses in patients with advanced PC. Biochemical assays and clinical observations suggest that the effects of PC- SPES are mediated at least in part through estrogenic activity, although the mechanism(s) remains largely undefined. In this study, we used cDNA microarray analysis to identify gene expression changes in LNCaP prostate carcinoma cells exposed to PC-SPES and estrogenic agents including DES. PC-SPES altered the expression of 156 genes after 24 h of exposure. Of particular interest, transcripts encoding cell cycle-regulatory proteins, alpha- and beta-tubulins, and the androgen receptor were down-regulated by PC-SPES. A comparison of gene expression profiles resulting from these treatments indicates that PC-SPES exhibits activities distinct from those attributable to DES and suggests that alterations in specific genes involved in modulating the cell cycle, cell structure, and androgen response may be responsible for PC-SPES-mediated cytotoxicity. PMID: 12124319 [PubMed - indexed for MEDLINE] Hsieh TC, Lu X, Chea J, Wu JM. Prevention and management of prostate cancer using PC-SPES: a scientific perspective. J Nutr. 2002 Nov;132(11 Suppl):3513S-3517S. Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA. tze-chen_hsieh Complementary and alternative therapies are increasingly used in USA by individuals diagnosed with cancer. PC-SPES is a multiherb dietary supplement used by many patients with prostate cancer (PC). The wide acceptance of PC-SPES for hormone-naive and end-stage PC relates to clinical trials showing significant efficacy and low toxicity. Although the clinical efficacy of PC-SPES is highly encouraging, its scientific basis has progressed more slowly. This article describes our understanding of the in vitro mechanisms of action of PC-SPES in androgen-dependent LNCaP cells. We first showed significant suppression of cancer cell growth by restriction of cell cycle progression at G(1)/S and drastic reductions in the expression of androgen receptor and PSA by PC-SPES, providing a mechanistic rationale for its observed clinical effects. Further investigation of the anti-PC properties of PC-SPES revealed that two of its multicomponent herbs, Gancao and Huangqin, inhibited cell growth and down-regulated PSA in a manner comparable with PC-SPES. Exhaustive characterization of S. baicalensis resulted in the isolation of baicalein. Here we report that baicalein effectively suppressed growth and PSA expression and induced G(1)/S arrest in LNCaP cells. Although baicalein cannot account for the entire activity of PC-SPES, it does display similar anti-PC activities. These data suggest that a single herb or bioactive compound could suffice for PC chemoprevention by effecting multiple changes in target cells to intervene in PC progression. Further evaluation is needed of the herbs in PC-SPES and the precise characterization of their bioactive ingredients. PMID: 12421879 [PubMed - indexed for MEDLINE] Hsieh TC, Wu JM. Mechanism of action of herbal supplement PC- SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen- dependent LNCaP cells. Int J Oncol. 2002 Mar;20(3):583-8. Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA. tze- chen_hsieh PC-SPES is a herbal mixture used as an alternative treatment by PC patients. Since PC-SPES is derived from eight individual herbs, each with distinct as well as overlapping properties, it is of interest to investigate whether a particular herb in the formulation principally accounts for the biological properties of PC-SPES. We tested the ability of extracts from individual herbs, using amounts estimated to be equivalent to that present in the herbal mixture, to suppress LNCaP cell growth and/or lower PSA expression, in comparison with cells treated with PC-SPES. Cells were incubated with 0, 1, and 5 ug/ml of single herbal extract for 72 h and proliferation/viability was measured by trypan blue exclusion. 5 ug/ml ethanol extracts of PC-SPES reduced cell growth of LNCaP cells by 72-80%, and cell viability decreased similarly. 5 ug/ml of individual herbal extract suppressed cell growth as follows: Dendranthema morifolium (85% reduction) > Sanqi (81%) > Gancao (73%) > Donglingcao (71%) > Huangqin (66%) > Lingzhi (63%) > Banlangen (51%) > Juchizonglan (14%). Only Gancao, Huangqin and Serenoa repens lowered intracellular and secreted PSA, while the remaining herbs increased PSA expression. Also, no uniform response in AR/PSA was observed in individual herb treated cells, contrary to PC-SPES, which elicited a coordinated change in AR/PSA. Lack of concordance between changes in prostate cell growth and prostate specific gene expression makes it unlikely that the activity of a single herb can account for the overall effects of PC-SPES. PMID: 11836572 [PubMed - indexed for MEDLINE] Huerta S, Arteaga JR, Irwin RW, Ikezoe T, Heber D, Koeffler HP. University of California Los Angeles (UCLA) Center for Human Nutrition, UCLA School of Medicine, 900 Veteran Avenue, 12-217 Warren Hall, Los Angeles, CA 90095, USA. shuerta Cancer Res. 2002 Sep 15;62(18):5204-9. PC-SPES inhibits colon cancer growth in vitro and in vivo. PC-SPES is a mixture of eight herbs with antiproliferative activity in PC cell lines and antitumor effects in animal models of PC. In addition, evidence of clinical efficacy in advanced PC has been reported. PC-SPES has also been shown to have antitumor activity against several other cancer cell lines including mammary and neuroepithelial cancer, melanoma, and leukemia cell lines. Because of these findings, we investigated the effects of PC-SPES in vitro in colon cancer cell lines SW480, SW620, and DLD-1 and in vivo in the Apc(min) mouse, a murine model for intestinal carcinogenesis. For the in vitro studies, colon cancer cell lines were exposed to an ethanolic extract of PC-SPES compared with a diluent control [ethanol < or = 0.3% (v/v)]. PC-SPES resulted in a marked suppression of cell proliferation in all colon cancer cells studied. PC-SPES (3 micro l/ml) caused a 95% inhibition of cell proliferation of the DLD-1 colon cancer cell line, and similar results were observed in the SW480 and SW620 colon cancer cell lines. Cell cycle analysis showed a drastic (> or =60%) accumulation of cells in the G(2)-M phase with a concomitant decrease of cells in the G(0)-G(1) phase in all colon cancer cell lines studied after treatment with PC-SPES (1.5 micro l/ml for 48 h). Western blot analysis showed a decrease in protein levels of beta-tubulin in the SW620 cell line exposed to PC-SPES. Terminal deoxynucleotidyl transferase-mediated nick end labeling analysis revealed an increase in apoptotic colon cancer cells incubated with PC-SPES. For the in vivo studies, female 4-5-week- old Apc(min) mice were randomized to two groups: a PC-SPES- treated group (n = 11) received 250 mg/kg/day (0.2 ml) PC-SPES via gastrointestinal gavage; and a control group (n = 10) received 0.2 ml of the vehicle solution (1.5% carboxymethylcellulose with 0.2% Tween 20) via gastrointestinal gavage. Both groups were treated five times a week for 10 weeks. After treatment, the gastrointestinal tract was dissected for polyp scoring by two observers blinded to treatment. The Apc(min) mice given PC-SPES had a 58% reduction in tumor number and a 56% decrease in tumor load. No effect on either food intake or body weight was observed in the treated versus sham groups. The present study is the first to report the potent activity of PC-SPES against colon cancer. Both cell cycle arrest and apoptosis occurred after treatment with PC-SPES. This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression. PMID: 12234985 [PubMed - indexed for MEDLINE] Ikezoe T, Chen S, Saito T, Asou H, Kyo T, Tanosaki S, Heber D, Taguchi H, Koeffler HP. Department of Medicine, Kochi Medical School, Nankoku, Kochi 783-8505, Japan. ikezoet- ms.ac.jp Int J Oncol. 2003 Oct;23(4):1203-11. PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells. PC-SPES has been shown to be active against PC cells in vitro as well as in patients. In this study, we discovered that it has anti-leukemia activity. HL-60, NB4, U937 and THP-1 human acute myeloid leukemia cells were cultured in the presence of various concentrations of PC-SPES (0.06-0.5 micro l/ml) for 4 days, and cell numbers were counted by Trypan blue exclusion. PC-SPES inhibited proliferation of these cells with an ED50 of 0.17, 0.09, 0.18, 0.32 micro l/ml, respectively. In clonogenic assay, PC-SPES inhibited growth of HL- 60 cells (ED50, 0.043 micro l/ml). On the other hand, PC-SPES (0.1 micro l/ml) stimulated growth of normal myeloid committed stem cells (CFU-GM) by 1.4-fold of control (p=0.03). Anti-leukemia effects also occurred against freshly isolated leukemia cells from acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Interestingly, when PC-SPES was combined with ATRA, the antiproliferative effect was markedly enhanced. For example, PC-SPES (0.125 micro l/ml) or ATRA (10(-8) mol/l) inhibited growth of HL-60 cells after 4 days of culture, by approximately 40 and 30%, respectively; simultaneous treatment with both, suppressed growth by 80%. In addition, PC-SPES induced differentiation of HL-60 and NB4 cells, as measured by expression of CD11b and reduction of NBT. ATRA synergistically enhanced this activity. For example, either PC-SPES (0.5 micro l/ml) or ATRA (10(-8) mol/l) induced 23 and 18% of HL-60 cells, respectively to express CD11b on day 2 of culture; and when both were combined, 60% of HL-60 cells were stimulated to express CD11b antigen. Furthermore, PC-SPES (0.5 micro l/ml) produced apoptosis of HL-60 and NB4 cells, as measured by TUNEL assay, with 17% of HL-60 cells and 52% of NB4 cells becoming apoptotic on their third day of culture. Importantly, PC-SPES stimulated expression of the novel myeloid specific transcription factor C/EBPepsilon in HL-60 and NB4 cells. Taken together, PC-SPES inhibits growth and induces differentiation and apoptosis of myeloid leukemia cells, and enhances the antiproliferative and prodifferentiative effects of ATRA on these cells. PC-SPES might be useful with ATRA to treat patients with acute promyelocytic leukemia (APL), and it could have a role in other types of cancers including MDS. PMID: 12964005 [PubMed - in process] Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE Jr, Pantuck AJ, Tyler VE. PC- SPES: herbal formulation for prostate cancer. Urology. 2002 Sep;60(3):369-75; discussion 376-7. Comment in: Urology. 2003 Jun;61(6):1292. Urological Sciences Research Foundation, Culver City, California 90232, USA. PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy to treat PC. The product induces a castrate status in most, if not all, men, resulting in a 50% or greater PSA reduction in the great majority of men with androgen-dependent PC and in >50% of the men with androgen-independent PC. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4% incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in PC cell lines. Thousands of men are using this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen- independent PC, an area in which future research should be primarily directed. Publication Types: Review Review, Tutorial PMID: 12350462 [PubMed - indexed for MEDLINE] Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA, DiPaola RS. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem. 2002 Feb 13;50(4):677-84. Department of Food Science and Center for Advanced Food Technology, Rutgers University, 65 Dudley Road, New Brunswick, New Jersey 08901-8520, USA. Herbal therapies are commonly used by patients with cancer, despite little understanding about biologically active chemical derivatives. We recently showed that PC-SPES, which contains Gancao, had anti- PC activity attributable to estrogen(s) that produced a chemical castration. A recent study also showed that Gancao alone decreased circulating testosterone in men. Other studies showed PC-SPES antitumor activity in vitro associated with decreased expression of anti-apoptotic protein Bcl-2 and in patients independent of chemical castration. This suggests that other mechanisms of antitumor activity exist separate from chemical castration. In the present study, we assessed Gancao extract for effects on Bcl-2 to identify novel cytotoxic derivatives. Gancao extract induced Bcl-2 phosphorylation as shown by immunoblot and G2/M cell cycle arrest, similarly to clinically used antimicrotubule agents such as paclitaxel. Bioassay-directed fractionations resulted in a biologically active fraction for Bcl-2 phosphorylation. HPLC separation followed by mass spectrometry and NMR identified 6 compounds. Only one molecule was responsible for Bcl-2 phosphorylation; it was identified as 1-(2,4- dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl) 1-propanone (beta- hydroxy-DHP). The effect on Bcl-2 was structure specific, because alpha-hydroxy-DHP, 1-(2,4-dihydroxyphenyl)-2-hydroxy-3-(4'- hydroxyphenyl) 1-propanone, in contrast to beta-hydroxy-DHP, was not capable of Bcl-2 phosphorylation. Pure beta-hydroxy-DHP induced Bcl-2 phosphorylation in mammary and prostate tumor cells, G2/M cell cycle arrest, apoptosis shown by Annexin V and TUNEL assay, decreased cell viability shown by a tetrazolium (MTT) assay, and altered microtubule structure. Gancao contains beta-hydroxy-DHP, which induced Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest, in mammary and prostate tumor cells, similarly to the action of more complex (MW >800) antimicrotubule agents used clinically. PMID: 11829627 [PubMed - indexed for MEDLINE] Schiff JD, Ziecheck WS, Choi B. Pulmonary embolus related to PC-SPES use in a patient with PSA recurrence after radical prostatectomy. Urology. 2002 Mar;59(3):444. James Buchanan Brady Department of Urology, New-York Presbyterian Hospital, Cornell Medical Center, New York, New York, USA. Patients diagnosed with a rising PSA level after radical prostatectomy represent a therapeutic dilemma. Herbal therapies including PC- SPES have gained popularity as alternatives to conventional hormonal ablation in such patients as a result of the perceived benefits of using natural products and proven clinical response in decreasing PSA levels. PC-SPES is one of the most popular herbs with known estrogenic activity in vitro and in vivo. Estrogenic compounds increase the risk of thromboembolic events. However, no specific guidelines are available with regard to the risk of thromboembolic events for patients using PC-SPES. We report a case of a patient treated with PC-SPES for PSA recurrence after radical prostatectomy who presented with pulmonary embolus and a right common femoral deep venous thrombus. PMID: 11880092 [PubMed - indexed for MEDLINE] Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr, Ho NW. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human Breast and prostate cancer cells. J Altern Complement Med. 2003 Aug;9(4):491-7. Cancer Research Laboratory, Methodist Research Institute, Clarian Health Partners Inc., Indianapolis, IN 46202, USA. dsliva OBJECTIVE: Lingzhi (Jap: Reishi) has been used in East Asia as a home remedy to prevent or cure cancer. Furthermore, Lingzhi is one of the herbs in the herbal mixture PC- SPES that has become an alternative herbal therapy for PC. Because the dried powder of Lingzhi is commercially available as a dietary supplement itself, the purpose of this study was to evaluate the biologic activity of samples of Lingzhi from different sources. METHODS: Samples of Lingzhi were characterized morphologically and evaluated for their ability to inhibit cell migration of highly invasive mammary cancer MDA-MB-231 cells and PC PC-3 cells. Because the inhibition of cell motility is directly linked to the inhibition of the signaling pathway for constitutively active NF-kappaB in mammary and PC cells, we determined how different samples of Lingzhi inhibit constitutively active NF-kappaB in a reporter gene assay. RESULTS: Some samples of Lingzhi strongly inhibited cancer cell migration comparable to the inhibition of constitutively active NF-kappaB, whereas other samples showed less or no activity in highly invasive estrogen receptor-negative mammary cancer cells or androgen receptor-negative PC cells, respectively. Interestingly, we did not find any correlation between the purity and composition (spores versus powder) of Lingzhi and biologic activity. CONCLUSIONS: Lingzhi had strong activity against mammary and PC cells. Nevertheless, the composition of samples did not correlate with their ability to inhibit cell migration and activation of NF-kappaB in vitro. PMID: 14499024 [PubMed - in process] Thomson JO, Dzubak P, Hajduch M.. Prostate cancer and the food supplement, PC-SPES. Minireview. Neoplasma. 2002;49(2):69-74. Department of Pediatrics, Faculty of Medicine, Palacky University and Faculty Hospital in Olomouc, Czech Republic Cancer of the prostate has now become the most frequently diagnosed cancer in males in America and its incidence has increased in many westernised countries. Surgery, radiotherapy and androgen ablation form the mainstay of its treatment. However, these treatment modalities are ineffective in a large percentage of patients due to grade of tumor at presentation, sensitivity to radiotherapy, hormone-insensitive profile of tumor cell population, etc. Because of the woeful ineffectiveness of these standard treatment modalities on the overall survival rate from PC in the past 50 years, a more radical approach to the treatment of this cancer is justified. To this end some of the latest innovative approaches are now being tested as tools in PC research, including those pioneered in molecular and cellular biology and immunology. There has also arisen a considerable interest in the modification of diet and the use of herbs and a great interest has been stimulated in PC-SPES, a herbal food supplement sold in the USA. This product, which is composed of eight herbs, is recommended as a food supplement for those suffering from PC and there are many anecdotal, scientific and clinical claims for its efficacy. This is a review of some of the in vivo and in vitro research carried out on this product. Publication Types: Review Review, Tutorial PMID: 12088108 [PubMed - indexed for MEDLINE] Wadsworth T, Poonyagariyagorn H, Sullivan E, Koop D, Roselli CE. In vivo effect of PC-SPES on prostate growth and hepatic CYP3A expression in rats. J Pharmacol Exp Ther. 2003 Jul;306(1):187-94. Epub 2003 Apr 03. Department of Physiology and Pharmacology L334, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA. PC-SPES, a proprietary mixture composed of eight different herbs, is used worldwide as an alternative treatment by PC patients. It has been suggested that the clinical and in vitro antitumor activity exhibited by PC-SPES may be due to estrogenic activity, which in turn may be mediated by the presence of undeclared prescription drug contaminants. Here, we evaluated the in vivo effects of two different commercial lots of PC-SPES in male and female rats. Our high-pressure liquid chromatography analysis coupled with gas chromatography/mass spectrometry analysis by an independent laboratory suggested that PC-SPES lot 5430125 was contaminated with DES, whereas lot 5431249 was not. Treatment of male rats with PC-SPES lot 5430125 or DES alone reduced the weight of androgen target organs and decreased circulating levels of sex steroids and LH, whereas lot 5431249 was without effect. Also, lot 5430125 and DES, but not lot 5431249 increased uterine weight in female rats. These results suggest that the inhibitory effects on androgen targets are mediated through suppression of the hypothalamic-pituitary axis and this suppression is probably due to DES contamination. We assessed the effects of both lots of PC-SPES and DES on hepatic cytochrome P450 expression and activity. Both lots of PC-SPES and DES reduced CYP3A activity and protein levels. Because the response of CYP3A to PC-SPES was not dependent on whether it contained DES, a phytochemical component of PC-SPES is most likely responsible for this effect. Inhibition of CYP3A has important implications for potential herbal- drug interactions. PMID: 12676889 [PubMed - indexed for MEDLINE] Yip I, Cudiamat M, Chim D. PC-SPES for treatment of prostate cancer: herbal medicine. Curr Urol Rep. 2003 Jun;4(3):253-7. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 522, Los Angeles, CA 90024, USA. iyip The number of patients who seek treatment with complementary and alternative medicine has increased during the past decade. The trend is primarily driven by consumers who start to change their views toward conventional pharmaceutical approaches that are offered to them. Among all complementary and alternative therapies used in the management of PC, Prostate Cancer-SPES (PC-SPES) has attracted much national attention because of its potency, controversy, and recall by the US Food and Drug Administration. PC-SPES contains extracts from a mixture of eight common herbs that have been used for thousands of years. This article is devoted to reviewing the basic and clinical data of using PC-SPES in PC therapy. It also explores the difference in philosophies between Western medicine and herbal medicine and explains the inherent difficulties in evaluating herbal medicine. The article concludes that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. Thus, new standards need to be developed for the evaluation of herbal medicine. Publication Types: Review Review, Tutorial PMID: 12756091 [PubMed - indexed for MEDLINE] Best regards, Email: < WORK : Teagasc Research Management, Sandymount Ave., Dublin 4, Ireland Mobile: 353-; [in the Republic: 0] HOME : 1 Esker Lawns, Lucan, Dublin, Ireland Tel : 353-; [in the Republic: 0] WWW : http://homepage.eircom.net/~progers/searchap.htm Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 7, 2003 Report Share Posted October 7, 2003 I agree if you mean that systematic scientific investigation should allow for the special one-to-one nature of CM treatment. Western scientists are slowly coming to accept that (Bigler et al, 2003). Yip et al (2003) conclude that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. THUS, NEW STANDARDS NEED TO BE DEVELOPED FOR THE EVALUATION OF HERBAL MEDICINE. >>>Even within there own paradigms things are changing. For example my Dad as published studies on schizophrenia using methodologies that are not reductionist and never the less they were published. This was a big step but things are changing Alon Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 7, 2003 Report Share Posted October 7, 2003 Well put Phil. I see you are getting into this fascinating subject ! One of the commentators you quoted, Eric Small dropped a PC-SPES study comparing its effect to DES before it was concluded, saying " .. there was no point comparing like with like " . Indometacin has been found in PC-SPES - not a surprise really since the Chinese regard indometacin as an OTC pharmaceutical and put it in other meds as well that are used for PC / pelvic stagnation (e.g. Xin Huang Pian). The fact that PC-SPES has never been proven to contain DES in quantities anywhere near significant enough to account for its powerful estrogenic action is a matter that WM is unable to address because of its obsessive conviction that its own mechanistic paradigm is prime. CM is not taken seriously by WM unless it can be cast in WM shape. As long as the docs were able to perceive CM products like PC-SPES doing the same job as WM 's DES there was a willingness to absorb it. When WM realised PC-SPES was outside of their conceptual remit they had to find a way to eject it so they invented the DES scam. Just remember that the well known conventional urologist Willaim Fair survived colon cancer on a product called SPES (another from the Sophie Chen camp) for many years beyond expectation of all. SPES was implicated in the contamination scam and forced off the market as well. I do not wish to appear to be making excuses for PC-SPES. I agree with most opinion in the TCM world that it is a 'bad formula' (although SPES may be a different story I do not know). The problem with PC-SPES was that it tried to use a dubious WM concept in the context of a TCM herbal. PSA is not all that it seems - see recent Files upload. PSA is used as a marker for PC but no-one has bothered to understand the biological mechanism of the protein in the round. Most early research shows PSA to have cancer promoting properties, but recent research points to a much wider role for PSA, and some anticancer propereties as well. Just as most WM urologists and oncologists fail to understand that castration and estrogenisation of the male is not the way to go treating a disease of deficiency, so they also fail to understand that PSA is not merely a PC marker in the context of symptomatic disease. PSA is also quite possibly an indicator of something controlling disease process in a context of asymptomatic disease. It is quite possible that a high PSA in earely-intermediate disease is preventing progression to more malignant states, and that suppression of PSA will merely speed the malignancy process. The fact that PSA ceases to be expressed in significant amount in advanced progressive disease should be ringing bells for anyone in TCM who thinks they can use PSA alone as an objective marker of treatment success. We shouldn't get stuck on PC-SPES no matter how interesting. There is another breed of TCM products that claim to treat the Ki deficiency state. Do they ? Here is an example - I quuote from the respective web pages : http://www.seacoastvitamins.com/Misc/prostate.html Ingredients per cap: Proprietary Herbal Blend (7.5:1 extracts)... 600mg Semen Cuscutae Chinensis (Dodder Seed / Tu Si Zi) Herba Epimedii (Epimedium / Yin Yang Huo) Fructus Serenoae (Saw Palmetto Berry) Radix Codonopsitis Picsulae (Codonopsis Root / Dang Shen) Radix Angelicae Sinensis (Tang Kuel Root / Dang Gui) Rhizoma Dioscorae Hypoglaucae (Tokoro Yam Rhizome / Bel Zia) Sclerotium Porlae (Hoelen, Tuckahoe / Fu Ling) Radix Paeoniae Rubrae (Red Peony Root / Chi Shao) Fructus Alpiniae Oxyphyllae (Alpinia Fruit, Black Cardamon / Yi Zhi Ren) Radix Linderae Strychnifoliae (Lindera Root / Wu Yao) Radix Glyoyrrhizae Uratensis (Licorice Root / Gan Cao) From the perspective of Oriental Medicine, the prostate is primarily nourished by the Spleen, Kidney, and Liver channels. With modern lifestyles and advancing years, certain patterns occur which affect the prostate gland. Decline of Spleen Yang can bring about an accumulation of Dampness in the Lower Burner. Further decline of Kidney Yang, a normal occurence with aging and stress, diminishes urinary function and sexual energy. This formula treats Dampness and stasis in the Lower Burner brought about by Deficiency of Spleen and Kidney Yang. This condition is characterized by sexual dysfunction, or frequent or inhibited urination. In western medicine, this often corresponds to Benign Hypertrophic Prostate (BHP) or enlarged prostate. For many men, these symptoms begin at age 40. Indications: Backache, Erectile dysfunction, loss of Libido, throbbing in Prostate, frequent Urination or difficulty starting and stopping flow. Information presented on this site has not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent disease. http://www.equiguardonline.com/equiing.html Equiguard Capsules Ingredients Herba Epimedii Indication Invigorating the kidney to strengthen yang, strengthening the muscles, tendons and bones, and dispelling wind to eliminate dampness (relieve rheumatic condition). Impotence and nocturnal emission, deficient-cold sterility, frequent urine and incontinence, asthma and cough due to kidney deficiency, soreness of the lower back and knees, arthralgia due to wind-dampness, hemiplegia, numbness of the limbs. Pharmacological action The applicable part of Herba Epimedii is the leaf. Researchers think flavonoids, icariin, and polysaccharides are the active constituents. Some evidence suggests Herba Epimedii might cause peripheral vasodilation, increase coronary blood flow, increase platelet aggregation and improve male sexual function. Herbal Epimedii also seems to inhibit catecholamine effects. It seems to have some hypotensive, immunomodulating, antimicrobial, anti-inflammatory, antitussive and expectorant effects. Evidence suggests Herba Epimedii might have activity against HIV. Fructus Rosae Laevigatae Indication Relieve nocturnal emission and leucorrphagia, and reduce the frequency of urination; for kidney deficiency manifested as nocturnal emission, enuresis and leucorrphagia, usually used with Semen Euryales together. Astringe the intestine to relieve diarrhea; for chronic diarrhea due to spleen deficiency. For chronic dysentery. Pharmacological Action Its decoction inhibits the growth of influenza virus and Bacillus dysenteriae in vitro. Promoting the secretion of gastric juice and enhancing the digestive function, also as an astringent. Fructus Rubi Indication Benefit the kidney, preserve essence and decrease micturition; for kidney deficiency manifested as nocturnal emission, enuresis and frequent micturition, usually used together with Fructus Alpiniae and Ootheca Mantidis; for impotence, premature ejaculation and seminal emission due to kidney deficiency, used together with Semen Cuscutae and Semen Astragali Cornplanati. Promote visual acuity for blurring of vision due to deficiency of liver and kidney, used together with Fructus Lycti, Fructus Schisandrae and Cuscutae. Pharmacological Action Possessing an estrogen-like effect. Fructus Psoraleae Indication Invigorate the kidney and strengthen yang. For sufficiency of kidney-yang manifested as cold pain of the waist and knees, impotence, emission, enuresis, frequent micturition, cough, dyspnea and shortness of breath, metorrphagia and sterility. Warm the spleen and kidney to stop diarrhea; for chronic diarrhea and diarrhea before dawn due to insufficiency of spleen-yang and kidney-yang. Recently also used for leukocytopenia, bronchial asthma and metorrhagia. External application of its alcoholic infusion for corns and leukoplakia vulvae; intramuscular injection and external application of psoralen for leukoderma and psoriasis. Pharmacological Action Corylifolinin (isobavachalacone, one of the components) dilates coronary artery significantly. Promoting phagocytosis of macrophage. Exciting the intestine smooth muscles in vivo and in vitro and relaxing the uterus of guinea pigs in vitro. Radix morindae Officinalis Indication Warm the kidney and strengthen yang; for deficiency of kidney-yang manifested as impotence, emission, enuresis, frequent micturition and sterility. Strengthen the tendons and bones, expel cold and dampness; for hypofunction of liver and kidney manifested as weakness of extremities, lassitude and cold pain of the waist and knees; or chronic rheumatism with arthralgia, weakness, cold pain of the joints, fatigue and pale tongue. Pharmacological Action Exerting androgen-like effect. Promoting the luteinizing action of the hypothalamus-pituitary system. Promoting the development of immature granulocytes. Fructus Schisandrae Indication Benefit vital energy and promote production of body fluid; for insufficiency of vital energy and body fluid manifested as fatigue, shortness of breath and feeble pulse, palpitation, hyperhidrosis (spontaneous persperation or night sweat), thirst, diabetes, etc., usually used together with Radix Ginseng and Radix Ophiopogonis. Astringe lung-energy, relieve dyspnea and cough; for cough and dyspnea of lung-deficiency type, lung-cold type and the dype of deficiency of both lung and kidney. Invigorate kidney and preserve essence; for kidney-deficiency syndrome with emission, chronic diarrhea, leucorrphagia, etc. Nourish the heart and calm the mind; for heart-deficiency syndrome with palpitation, insomnia and dreaminess. In addition, its powder preparation is used for chronic hepatitis with elevation of serum transaminase. Pharmacological Action Its decoction exerts bacteriostatic effect on Pseudomonas aeruginosa, Staphylococcus aurous, Flexner's bacillus and Typhoid bacillus in vitro. Schizandrin, one of its active components, can protect liver from damage. Enhancing lymphocyte-blastogenesis rate. Cardiotonic and sedative. Fructus Ligustri Lucidi Indication Tonify the liver and the kidney, darken the hair and promote visual acuity; for deficiency of liver-yin and kidney-yin manifested as dizziness, tinnitus, blurring of vision, weakness of the loin and knees, hectic fever, nocturnal emission, alopecia and poliosis, usually used with Herba Ecliptae. Recently used for seborrheic alopecia, central retinitis, early cataract, etc. Tranquilize the mind by nourishing the heart; for insufficiency of heart-yin manifested as insomnia, palpitation and precordial pain. Recently, also used for angina pectoris, hyperlipemia and neurasthenia, especially those of in-deficiency type. In addition, also used for leukocytopenia, viral hepatitis with yin-deficiency syndrome; its component oleanolic acid for various kinds of hepatitis. Pharmacological Action Its component oleanolic acid can prevent and relieve cyclophosphamide-induced leukocytopenia in mice. Enhancing the anoxia tolerance of mice under atmospheric pressure. Semen Cuscutae Indication Invigorate the kidney and supplement essence; for insufficiency of kidney-yang or kidney essence manifested as ipotence, emission, enuresis, frequent micturition, sterility, leucorrhagia, soreness of the loin and knees, blurred vision, tinnitus and deafness. Soothe the fetus; for deficiency of the liver and kidney manifested as threatened abortion and habitual abortion, used together with Ramulus Taxilli, Radix Dipsaci and Colla Corri Asini. Nourish the liver and improve visual acuity; for blurring of vision and hypopsia due to insufficiency of the liver and kidney. Benefit the spleen to relieve diarrhea; for loose stools or diarrhea due to deficiency of the spleen and kidney, usually used together with Fructus Psoraleae, Semen Myristicae and Phizma Atractylodis Macrocephalae. Recently, also used for aplastic anemia and chyluria. Pharmacological Action Cardiotonic. Promoting lymphocyte-blastogenesis. Radix Astragali Indication Invigorate vital energy and spleen; for spleen-deficiency with poor appetite, loose stools, fatigue and bleeding, usually used together with Radix Codonopsis Pilosulae and Rhizoma Atractylodis Macrocephalae; for deficiency of both vital energy and blood, used together with Radix Angelicae Sinensis. Invigorate vital energy to activate yang; for collapse of middle-jiao energy manifested as prolapse of rectum, hysteroptosis or gastroptosis, usually used together with Codonopsis Pilosulae, Rhizoma Cimicifugae and Radix Bupleuri. Invigorate vital energy to strengthen the body; for common cold in debilitated patient, superficies-asthenia with profuce sweating, usually used together with Atractylodis Macrocephalae. Relieve skin infection and promote tissue regeneration; for unruptured abscess, unhealed carbuncle, skin erosion, unhealed wound, eruptive diseases and skin infection of yin-type. Recently, used for peptic ulcer and atrophic gastritis. Promote diuresia and relieve edema; for edema of spleen-deficiency type. In addition, it can invigorate vital energy to promote production of body fluid and quench thirst and is indicated for diabetes; hemiplegia due to deficiency of vital energy and blood stasis. Also used for asthma and leukocytopenia. Others; for albuminuria in chronic nephritis, diabetes caused by internal heat. Pharmacological Action Increasing the amount of leukocytes and polymorphocytes in peripheral blood and promoting lymphocyte-blastogenesis. Its polysaccharide promotes the healing of skin ulcer. Cardiotonic. Dilating coronary artery and capillaries. [] 07 October 2003 02:15 ; vBMA; traditional_Chinese_Medicine Cc: swynndvm Should CM be subject to systematic scientific investigation? Hi All, & Hi Wainright, [susan, if the VBMA server bounces this because of size, could YOU please mount it for me. IMO, Westerm Medicine has reached an impasse in the Tx of prostate cancer [PC] and serious work, at last, is being directed to herbal medicine in PC Tx.] Wainright wrote: > ... if we wish Chinese medicine as we know it to survive ... IMO, Chinese medicine WILL survive, but NOT as we know it now! CM will evolve to embrace established [and yet to be established] medical and social facts from the West. Parallel with the evolution of CM, we will probably see evolution in Western medicine (WM) to embrace established [and yet to be established] medical and social facts from the East. In the evolutions of CM and WM, we will see more and more cross- linkages - integration - so that in time the two systems will grow closer and closer together. It remains to be seen whether this will take 5, 50, 500, or 5000 years, but sooner or later we will have an integrated medicine of the best available. > ... an important task is for us to exert political pressure to NOT > subject CM to any type of systematic scientific investigation ... With respect, I disagree. IMO, systematic scientific investigation offers the BEST hope for the development of effective, objective medicine. It will identify and eliminate (or correct) the fallacies and will highlight and improve the effective methods. > ... or at the very least, to preserve a high measure of autonomy > for CM in the process. Wainwright Wainright, in developing my argument, I will use recent references from Medline on prostate cancer. Thomson et al (2002) wrote: " Because of the woeful ineffectiveness of standard treatment modalities on the overall survival rate from PC in the past 50 years, a more radical approach to the treatment of this cancer is justified " . By " radical approach " , they meant consideration of herbal medicine - in this case PC-SPES!! I agree if you mean that systematic scientific investigation should allow for the special one-to-one nature of CM treatment. Western scientists are slowly coming to accept that (Bigler et al, 2003). Yip et al (2003) conclude that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. THUS, NEW STANDARDS NEED TO BE DEVELOPED FOR THE EVALUATION OF HERBAL MEDICINE. Critical scientific research is starting to identify the most important active ingredients in effective CHM formulae, for example baicalin and oridonin in PC-SPES. See Hsieh et al (2002) and Marks et al (2003). PC-SPES got a bad name when it was found to have been contaminated by DES, indomethacin, warfarin etc. Before then, many cancer specialists ACCEPTED that it was of great clinical value. After the scandal broke, some specialists believed that its clinical effects were due to the CONTAMINANTS, especially DES (Wadsworth et al, 2003). However, other papers suggest that this is not the case; the clinical effects of PC-SPES do not depend on DES (Bonham et al, 2002). Western research will show that herbal formulas are not all goodness and light, with no side effects. For example, though the clinical efficacy of PC-SPES in prostate cancer is well accepted now [in spite of the FDA ban!], its oestrogenic effects have their negative consequences in men. It is beginning to look that PC- SPES is a form of phytochemical castration, just as chemical androgen ablation is (Marks et al, 2003; Raffi et al, 2002; Schiff et al, 2002). Also, scientists are beginning to realise that the activity of a single herb cannot account for the overall effects of the effective formula (Hsieh & Wu, 2002). One of the great benefits of systematic western research on herbs is that a formula initially used for one condition (for example PC- SPES in prostate cancer) may be found to have OTHER clinical uses. For example Huerta et al (2002).al found that PC-SPES is also effective in colon cancer. Ikezoe et al (2003) found that PC- SPES also is effective in leukaemia. Sliva et al (2003) found that Ganoderma (Lingzhi) in PC-SPES inhibits mammary cancer as well as PC. These are GREAT breakthroughs for herbal medicine in the west! Here follows a sobering abstract about the current status of WESTERN approaches to PC: Small EJ, Harris KA. Secondary hormonal manipulation of prostate cancer. Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):24-30. Urologic Oncology Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA. Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced PC is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease progression. Patients with hormone-resistant PC (HRPC) have a median survival of approximately 18 months, and no therapy has yet shown a definitive survival advantage. However, in the past several years, a number of promising new treatment strategies have emerged. One of the most important new treatment strategies involves SECONDARY HORMONAL MANIPULATION after the failure of primary androgen deprivation. This approach is predicated on the recognition that HRPC is a heterogeneous disease, and some patients may respond to alternative hormonal interventions despite the presence of castrate levels of testosterone. Copyright 2002, Elsevier Science (USA). All rights reserved. Publication Types: Review Review Literature PMID: 12198635 [PubMed - indexed for MEDLINE] [Phil's comment: Watch this space! For “SECONDARY HORMONAL MANIPULATION” (above), read: “HORMONAL MANIPULATION BY CHINESE MEDICINE!” Because of western bigotry, skepticism, prejudice or arrogance, IMO, Chinese Science alone will NOT be sufficient to put CM " on the map " in the Western World [i.e. to make it acceptable to western scientists]. Only WESTERN science, or at least critical Western confirmation of Chinese findings, will do that. Best regards, Phil PS: See the other cited references, below. Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene. 2003 Feb 27;22(8):1261-72. Department of Molecular Physiology and Biological Physics and Cancer Center, University of Virginia, Health Sciences Center, Charlottesville, VA 22908, USA. The use of botanical mixtures is commonplace in patients with PC, yet most of these products have not been tested rigorously in clinical trials. PC-SPES has been shown to be effective in clinical trials in patients with PC. Here we use PC-SPES as a model system to show 'proof of principle' as to how gene expression profiling coupled with promoter assays can evaluate the effect of herbal cocktails on human PC. We also show how such approaches may be used to standardize herbal extract activity by comparing the gene profile of PC-SPES with that of PC- CARE, a product with a similar herbal composition. Since prior studies have shown that PC-SPES contains estrogenic organic compounds, and such compounds are known to affect PC, an important issue is whether these are the primary drivers of the gene profile. Our data suggest that gene expression profiles of LNCaP human PC cells in response to PC-SPES are different from those found when DES, a synthetic estrogen, is used. This suggests that the estrogenic moieties within PC-SPES do not drive this expression signature. In contrast, the expression profile of PC- CARE was almost identical to that of DES, highlighting that mixtures containing similar herbal compositions do not necessarily result in similar biological activities. Interestingly, these three agents cause similar in vitro morphological changes and growth effects on LNCaP. To validate the expression profiling data, we evaluated the protein expression and promoter activity of PSA, a gene induced by PC-SPES but repressed by DES. In order to gain a mechanistic understanding of how PC-SPES and DES affect PSA expression differently, LNCaP cells were transiently transfected with wild-type and mutagenized PSA promoter, ARE concatemers and appropriate controls. We provide evidence that androgen response elements (ARE) II and III within the promoter region are responsible for the suppressive effects of DES and stimulatory effects of PC-SPES. In addition, we show that the effects on PSA transcription are ARE specific in the case of DES while PC-SPES affects this promoter nonspecifically. Expression profiling coupled with mechanistic target validation yield valuable clues as to the mode of action of complex botanical mixtures and provides a new way to compare objectively mixtures with similar components either for effect or quality assurance prior to their use in clinical trials. PMID: 12606954 [PubMed - indexed for MEDLINE] Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res. 2002 Jul 15;62(14):3920-4. Divisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. Clinical trials of the herbal preparation PC-SPES showed substantial responses in patients with advanced PC. Biochemical assays and clinical observations suggest that the effects of PC- SPES are mediated at least in part through estrogenic activity, although the mechanism(s) remains largely undefined. In this study, we used cDNA microarray analysis to identify gene expression changes in LNCaP prostate carcinoma cells exposed to PC-SPES and estrogenic agents including DES. PC-SPES altered the expression of 156 genes after 24 h of exposure. Of particular interest, transcripts encoding cell cycle-regulatory proteins, alpha- and beta-tubulins, and the androgen receptor were down-regulated by PC-SPES. A comparison of gene expression profiles resulting from these treatments indicates that PC-SPES exhibits activities distinct from those attributable to DES and suggests that alterations in specific genes involved in modulating the cell cycle, cell structure, and androgen response may be responsible for PC-SPES-mediated cytotoxicity. PMID: 12124319 [PubMed - indexed for MEDLINE] Hsieh TC, Lu X, Chea J, Wu JM. Prevention and management of prostate cancer using PC-SPES: a scientific perspective. J Nutr. 2002 Nov;132(11 Suppl):3513S-3517S. Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA. tze-chen_hsieh Complementary and alternative therapies are increasingly used in USA by individuals diagnosed with cancer. PC-SPES is a multiherb dietary supplement used by many patients with prostate cancer (PC). The wide acceptance of PC-SPES for hormone-naive and end-stage PC relates to clinical trials showing significant efficacy and low toxicity. Although the clinical efficacy of PC-SPES is highly encouraging, its scientific basis has progressed more slowly. This article describes our understanding of the in vitro mechanisms of action of PC-SPES in androgen-dependent LNCaP cells. We first showed significant suppression of cancer cell growth by restriction of cell cycle progression at G(1)/S and drastic reductions in the expression of androgen receptor and PSA by PC-SPES, providing a mechanistic rationale for its observed clinical effects. Further investigation of the anti-PC properties of PC-SPES revealed that two of its multicomponent herbs, Gancao and Huangqin, inhibited cell growth and down-regulated PSA in a manner comparable with PC-SPES. Exhaustive characterization of S. baicalensis resulted in the isolation of baicalein. Here we report that baicalein effectively suppressed growth and PSA expression and induced G(1)/S arrest in LNCaP cells. Although baicalein cannot account for the entire activity of PC-SPES, it does display similar anti-PC activities. These data suggest that a single herb or bioactive compound could suffice for PC chemoprevention by effecting multiple changes in target cells to intervene in PC progression. Further evaluation is needed of the herbs in PC-SPES and the precise characterization of their bioactive ingredients. PMID: 12421879 [PubMed - indexed for MEDLINE] Hsieh TC, Wu JM. Mechanism of action of herbal supplement PC- SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen- dependent LNCaP cells. Int J Oncol. 2002 Mar;20(3):583-8. Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA. tze- chen_hsieh PC-SPES is a herbal mixture used as an alternative treatment by PC patients. Since PC-SPES is derived from eight individual herbs, each with distinct as well as overlapping properties, it is of interest to investigate whether a particular herb in the formulation principally accounts for the biological properties of PC-SPES. We tested the ability of extracts from individual herbs, using amounts estimated to be equivalent to that present in the herbal mixture, to suppress LNCaP cell growth and/or lower PSA expression, in comparison with cells treated with PC-SPES. Cells were incubated with 0, 1, and 5 ug/ml of single herbal extract for 72 h and proliferation/viability was measured by trypan blue exclusion. 5 ug/ml ethanol extracts of PC-SPES reduced cell growth of LNCaP cells by 72-80%, and cell viability decreased similarly. 5 ug/ml of individual herbal extract suppressed cell growth as follows: Dendranthema morifolium (85% reduction) > Sanqi (81%) > Gancao (73%) > Donglingcao (71%) > Huangqin (66%) > Lingzhi (63%) > Banlangen (51%) > Juchizonglan (14%). Only Gancao, Huangqin and Serenoa repens lowered intracellular and secreted PSA, while the remaining herbs increased PSA expression. Also, no uniform response in AR/PSA was observed in individual herb treated cells, contrary to PC-SPES, which elicited a coordinated change in AR/PSA. Lack of concordance between changes in prostate cell growth and prostate specific gene expression makes it unlikely that the activity of a single herb can account for the overall effects of PC-SPES. PMID: 11836572 [PubMed - indexed for MEDLINE] Huerta S, Arteaga JR, Irwin RW, Ikezoe T, Heber D, Koeffler HP. University of California Los Angeles (UCLA) Center for Human Nutrition, UCLA School of Medicine, 900 Veteran Avenue, 12-217 Warren Hall, Los Angeles, CA 90095, USA. shuerta Cancer Res. 2002 Sep 15;62(18):5204-9. PC-SPES inhibits colon cancer growth in vitro and in vivo. PC-SPES is a mixture of eight herbs with antiproliferative activity in PC cell lines and antitumor effects in animal models of PC. In addition, evidence of clinical efficacy in advanced PC has been reported. PC-SPES has also been shown to have antitumor activity against several other cancer cell lines including mammary and neuroepithelial cancer, melanoma, and leukemia cell lines. Because of these findings, we investigated the effects of PC-SPES in vitro in colon cancer cell lines SW480, SW620, and DLD-1 and in vivo in the Apc(min) mouse, a murine model for intestinal carcinogenesis. For the in vitro studies, colon cancer cell lines were exposed to an ethanolic extract of PC-SPES compared with a diluent control [ethanol < or = 0.3% (v/v)]. PC-SPES resulted in a marked suppression of cell proliferation in all colon cancer cells studied. PC-SPES (3 micro l/ml) caused a 95% inhibition of cell proliferation of the DLD-1 colon cancer cell line, and similar results were observed in the SW480 and SW620 colon cancer cell lines. Cell cycle analysis showed a drastic (> or =60%) accumulation of cells in the G(2)-M phase with a concomitant decrease of cells in the G(0)-G(1) phase in all colon cancer cell lines studied after treatment with PC-SPES (1.5 micro l/ml for 48 h). Western blot analysis showed a decrease in protein levels of beta-tubulin in the SW620 cell line exposed to PC-SPES. Terminal deoxynucleotidyl transferase-mediated nick end labeling analysis revealed an increase in apoptotic colon cancer cells incubated with PC-SPES. For the in vivo studies, female 4-5-week- old Apc(min) mice were randomized to two groups: a PC-SPES- treated group (n = 11) received 250 mg/kg/day (0.2 ml) PC-SPES via gastrointestinal gavage; and a control group (n = 10) received 0.2 ml of the vehicle solution (1.5% carboxymethylcellulose with 0.2% Tween 20) via gastrointestinal gavage. Both groups were treated five times a week for 10 weeks. After treatment, the gastrointestinal tract was dissected for polyp scoring by two observers blinded to treatment. The Apc(min) mice given PC-SPES had a 58% reduction in tumor number and a 56% decrease in tumor load. No effect on either food intake or body weight was observed in the treated versus sham groups. The present study is the first to report the potent activity of PC-SPES against colon cancer. Both cell cycle arrest and apoptosis occurred after treatment with PC-SPES. This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression. PMID: 12234985 [PubMed - indexed for MEDLINE] Ikezoe T, Chen S, Saito T, Asou H, Kyo T, Tanosaki S, Heber D, Taguchi H, Koeffler HP. Department of Medicine, Kochi Medical School, Nankoku, Kochi 783-8505, Japan. ikezoet- ms.ac.jp Int J Oncol. 2003 Oct;23(4):1203-11. PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells. PC-SPES has been shown to be active against PC cells in vitro as well as in patients. In this study, we discovered that it has anti-leukemia activity. HL-60, NB4, U937 and THP-1 human acute myeloid leukemia cells were cultured in the presence of various concentrations of PC-SPES (0.06-0.5 micro l/ml) for 4 days, and cell numbers were counted by Trypan blue exclusion. PC-SPES inhibited proliferation of these cells with an ED50 of 0.17, 0.09, 0.18, 0.32 micro l/ml, respectively. In clonogenic assay, PC-SPES inhibited growth of HL- 60 cells (ED50, 0.043 micro l/ml). On the other hand, PC-SPES (0.1 micro l/ml) stimulated growth of normal myeloid committed stem cells (CFU-GM) by 1.4-fold of control (p=0.03). Anti-leukemia effects also occurred against freshly isolated leukemia cells from acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Interestingly, when PC-SPES was combined with ATRA, the antiproliferative effect was markedly enhanced. For example, PC-SPES (0.125 micro l/ml) or ATRA (10(-8) mol/l) inhibited growth of HL-60 cells after 4 days of culture, by approximately 40 and 30%, respectively; simultaneous treatment with both, suppressed growth by 80%. In addition, PC-SPES induced differentiation of HL-60 and NB4 cells, as measured by expression of CD11b and reduction of NBT. ATRA synergistically enhanced this activity. For example, either PC-SPES (0.5 micro l/ml) or ATRA (10(-8) mol/l) induced 23 and 18% of HL-60 cells, respectively to express CD11b on day 2 of culture; and when both were combined, 60% of HL-60 cells were stimulated to express CD11b antigen. Furthermore, PC-SPES (0.5 micro l/ml) produced apoptosis of HL-60 and NB4 cells, as measured by TUNEL assay, with 17% of HL-60 cells and 52% of NB4 cells becoming apoptotic on their third day of culture. Importantly, PC-SPES stimulated expression of the novel myeloid specific transcription factor C/EBPepsilon in HL-60 and NB4 cells. Taken together, PC-SPES inhibits growth and induces differentiation and apoptosis of myeloid leukemia cells, and enhances the antiproliferative and prodifferentiative effects of ATRA on these cells. PC-SPES might be useful with ATRA to treat patients with acute promyelocytic leukemia (APL), and it could have a role in other types of cancers including MDS. PMID: 12964005 [PubMed - in process] Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE Jr, Pantuck AJ, Tyler VE. PC- SPES: herbal formulation for prostate cancer. Urology. 2002 Sep;60(3):369-75; discussion 376-7. Comment in: Urology. 2003 Jun;61(6):1292. Urological Sciences Research Foundation, Culver City, California 90232, USA. PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy to treat PC. The product induces a castrate status in most, if not all, men, resulting in a 50% or greater PSA reduction in the great majority of men with androgen-dependent PC and in >50% of the men with androgen-independent PC. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4% incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in PC cell lines. Thousands of men are using this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen- independent PC, an area in which future research should be primarily directed. Publication Types: Review Review, Tutorial PMID: 12350462 [PubMed - indexed for MEDLINE] Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA, DiPaola RS. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem. 2002 Feb 13;50(4):677-84. Department of Food Science and Center for Advanced Food Technology, Rutgers University, 65 Dudley Road, New Brunswick, New Jersey 08901-8520, USA. Herbal therapies are commonly used by patients with cancer, despite little understanding about biologically active chemical derivatives. We recently showed that PC-SPES, which contains Gancao, had anti- PC activity attributable to estrogen(s) that produced a chemical castration. A recent study also showed that Gancao alone decreased circulating testosterone in men. Other studies showed PC-SPES antitumor activity in vitro associated with decreased expression of anti-apoptotic protein Bcl-2 and in patients independent of chemical castration. This suggests that other mechanisms of antitumor activity exist separate from chemical castration. In the present study, we assessed Gancao extract for effects on Bcl-2 to identify novel cytotoxic derivatives. Gancao extract induced Bcl-2 phosphorylation as shown by immunoblot and G2/M cell cycle arrest, similarly to clinically used antimicrotubule agents such as paclitaxel. Bioassay-directed fractionations resulted in a biologically active fraction for Bcl-2 phosphorylation. HPLC separation followed by mass spectrometry and NMR identified 6 compounds. Only one molecule was responsible for Bcl-2 phosphorylation; it was identified as 1-(2,4- dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl) 1-propanone (beta- hydroxy-DHP). The effect on Bcl-2 was structure specific, because alpha-hydroxy-DHP, 1-(2,4-dihydroxyphenyl)-2-hydroxy-3-(4'- hydroxyphenyl) 1-propanone, in contrast to beta-hydroxy-DHP, was not capable of Bcl-2 phosphorylation. Pure beta-hydroxy-DHP induced Bcl-2 phosphorylation in mammary and prostate tumor cells, G2/M cell cycle arrest, apoptosis shown by Annexin V and TUNEL assay, decreased cell viability shown by a tetrazolium (MTT) assay, and altered microtubule structure. Gancao contains beta-hydroxy-DHP, which induced Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest, in mammary and prostate tumor cells, similarly to the action of more complex (MW >800) antimicrotubule agents used clinically. PMID: 11829627 [PubMed - indexed for MEDLINE] Schiff JD, Ziecheck WS, Choi B. Pulmonary embolus related to PC-SPES use in a patient with PSA recurrence after radical prostatectomy. Urology. 2002 Mar;59(3):444. James Buchanan Brady Department of Urology, New-York Presbyterian Hospital, Cornell Medical Center, New York, New York, USA. Patients diagnosed with a rising PSA level after radical prostatectomy represent a therapeutic dilemma. Herbal therapies including PC- SPES have gained popularity as alternatives to conventional hormonal ablation in such patients as a result of the perceived benefits of using natural products and proven clinical response in decreasing PSA levels. PC-SPES is one of the most popular herbs with known estrogenic activity in vitro and in vivo. Estrogenic compounds increase the risk of thromboembolic events. However, no specific guidelines are available with regard to the risk of thromboembolic events for patients using PC-SPES. We report a case of a patient treated with PC-SPES for PSA recurrence after radical prostatectomy who presented with pulmonary embolus and a right common femoral deep venous thrombus. PMID: 11880092 [PubMed - indexed for MEDLINE] Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr, Ho NW. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human Breast and prostate cancer cells. J Altern Complement Med. 2003 Aug;9(4):491-7. Cancer Research Laboratory, Methodist Research Institute, Clarian Health Partners Inc., Indianapolis, IN 46202, USA. dsliva OBJECTIVE: Lingzhi (Jap: Reishi) has been used in East Asia as a home remedy to prevent or cure cancer. Furthermore, Lingzhi is one of the herbs in the herbal mixture PC- SPES that has become an alternative herbal therapy for PC. Because the dried powder of Lingzhi is commercially available as a dietary supplement itself, the purpose of this study was to evaluate the biologic activity of samples of Lingzhi from different sources. METHODS: Samples of Lingzhi were characterized morphologically and evaluated for their ability to inhibit cell migration of highly invasive mammary cancer MDA-MB-231 cells and PC PC-3 cells. Because the inhibition of cell motility is directly linked to the inhibition of the signaling pathway for constitutively active NF-kappaB in mammary and PC cells, we determined how different samples of Lingzhi inhibit constitutively active NF-kappaB in a reporter gene assay. RESULTS: Some samples of Lingzhi strongly inhibited cancer cell migration comparable to the inhibition of constitutively active NF-kappaB, whereas other samples showed less or no activity in highly invasive estrogen receptor-negative mammary cancer cells or androgen receptor-negative PC cells, respectively. Interestingly, we did not find any correlation between the purity and composition (spores versus powder) of Lingzhi and biologic activity. CONCLUSIONS: Lingzhi had strong activity against mammary and PC cells. Nevertheless, the composition of samples did not correlate with their ability to inhibit cell migration and activation of NF-kappaB in vitro. PMID: 14499024 [PubMed - in process] Thomson JO, Dzubak P, Hajduch M.. Prostate cancer and the food supplement, PC-SPES. Minireview. Neoplasma. 2002;49(2):69-74. Department of Pediatrics, Faculty of Medicine, Palacky University and Faculty Hospital in Olomouc, Czech Republic Cancer of the prostate has now become the most frequently diagnosed cancer in males in America and its incidence has increased in many westernised countries. Surgery, radiotherapy and androgen ablation form the mainstay of its treatment. However, these treatment modalities are ineffective in a large percentage of patients due to grade of tumor at presentation, sensitivity to radiotherapy, hormone-insensitive profile of tumor cell population, etc. Because of the woeful ineffectiveness of these standard treatment modalities on the overall survival rate from PC in the past 50 years, a more radical approach to the treatment of this cancer is justified. To this end some of the latest innovative approaches are now being tested as tools in PC research, including those pioneered in molecular and cellular biology and immunology. There has also arisen a considerable interest in the modification of diet and the use of herbs and a great interest has been stimulated in PC-SPES, a herbal food supplement sold in the USA. This product, which is composed of eight herbs, is recommended as a food supplement for those suffering from PC and there are many anecdotal, scientific and clinical claims for its efficacy. This is a review of some of the in vivo and in vitro research carried out on this product. Publication Types: Review Review, Tutorial PMID: 12088108 [PubMed - indexed for MEDLINE] Wadsworth T, Poonyagariyagorn H, Sullivan E, Koop D, Roselli CE. In vivo effect of PC-SPES on prostate growth and hepatic CYP3A expression in rats. J Pharmacol Exp Ther. 2003 Jul;306(1):187-94. Epub 2003 Apr 03. Department of Physiology and Pharmacology L334, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA. PC-SPES, a proprietary mixture composed of eight different herbs, is used worldwide as an alternative treatment by PC patients. It has been suggested that the clinical and in vitro antitumor activity exhibited by PC-SPES may be due to estrogenic activity, which in turn may be mediated by the presence of undeclared prescription drug contaminants. Here, we evaluated the in vivo effects of two different commercial lots of PC-SPES in male and female rats. Our high-pressure liquid chromatography analysis coupled with gas chromatography/mass spectrometry analysis by an independent laboratory suggested that PC-SPES lot 5430125 was contaminated with DES, whereas lot 5431249 was not. Treatment of male rats with PC-SPES lot 5430125 or DES alone reduced the weight of androgen target organs and decreased circulating levels of sex steroids and LH, whereas lot 5431249 was without effect. Also, lot 5430125 and DES, but not lot 5431249 increased uterine weight in female rats. These results suggest that the inhibitory effects on androgen targets are mediated through suppression of the hypothalamic-pituitary axis and this suppression is probably due to DES contamination. We assessed the effects of both lots of PC-SPES and DES on hepatic cytochrome P450 expression and activity. Both lots of PC-SPES and DES reduced CYP3A activity and protein levels. Because the response of CYP3A to PC-SPES was not dependent on whether it contained DES, a phytochemical component of PC-SPES is most likely responsible for this effect. Inhibition of CYP3A has important implications for potential herbal- drug interactions. PMID: 12676889 [PubMed - indexed for MEDLINE] Yip I, Cudiamat M, Chim D. PC-SPES for treatment of prostate cancer: herbal medicine. Curr Urol Rep. 2003 Jun;4(3):253-7. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 522, Los Angeles, CA 90024, USA. iyip The number of patients who seek treatment with complementary and alternative medicine has increased during the past decade. The trend is primarily driven by consumers who start to change their views toward conventional pharmaceutical approaches that are offered to them. Among all complementary and alternative therapies used in the management of PC, Prostate Cancer-SPES (PC-SPES) has attracted much national attention because of its potency, controversy, and recall by the US Food and Drug Administration. PC-SPES contains extracts from a mixture of eight common herbs that have been used for thousands of years. This article is devoted to reviewing the basic and clinical data of using PC-SPES in PC therapy. It also explores the difference in philosophies between Western medicine and herbal medicine and explains the inherent difficulties in evaluating herbal medicine. The article concludes that PC-SPES cannot be evaluated by the same standards established to test synthetic pharmaceutical compounds. Thus, new standards need to be developed for the evaluation of herbal medicine. Publication Types: Review Review, Tutorial PMID: 12756091 [PubMed - indexed for MEDLINE] Best regards, Email: < WORK : Teagasc Research Management, Sandymount Ave., Dublin 4, Ireland Mobile: 353-; [in the Republic: 0] HOME : 1 Esker Lawns, Lucan, Dublin, Ireland Tel : 353-; [in the Republic: 0] WWW : http://homepage.eircom.net/~progers/searchap.htm Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.